Eli Lilly & Co. v. Medtronic, Inc.

From Wikipedia, the free encyclopedia

Eli Lilly & Co. v. Medtronic, Inc.

Argued February 26, 1990
Decided June 18, 1990

Full case name:	Eli Lilly & Co. v. Medtronic, Inc.
Docket #:	89-243

Citations:	496 U.S. 661; 110 S. Ct. 2683; 110 L. Ed. 2d 605; 1990 U.S. LEXIS 3184; 58 U.S.L.W. 4838; 15 U.S.P.Q.2D (BNA) 1121

Prior history:	Certiorari to the Circuit Court of Appeal for the Federal Circuit.

Subsequent history:	Rehearing Denied, August 14, 1990, Reported at 1990 U.S. LEXIS 3730.

Holding

Court membership

Chief Justice: William Rehnquist
Associate Justices: William J. Brennan, Jr., Byron White, Thurgood Marshall, Harry Blackmun, John Paul Stevens, Sandra Day O'Connor, Antonin Scalia, Anthony Kennedy

Case opinions

Majority by: Scalia
Joined by: Rehnquist, Brennan, Marshall, Blackmun, Stevens
Dissent by: Kennedy
Joined by: White
O'Connor took no part in the consideration or decision of the case.

Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990), is a United States Supreme Court case related to Patent infringement in the Medical device industry. It held that 35 U.S.C. § 271(e)(1) of United States patent law exempted premarketing activity conducted to gain approval of a device under the Federal Food, Drug, and Cosmetic Act from a finding of infringement.